Evidence map›Paper›PMID 30531299›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Early and Late Virologic Failure After Virologic Suppression in HIV-Infected Asian Children and Adolescents.

Weiwei Mu, Adam W Bartlett, Torsak Bunupuradah, Kulkanya Chokephaibulkit, Nagalingeswaran Kumarasamy, Penh Sun Ly, Rawiwan Hansudewechakul, Lam Van Nguyen, Pagakrong Lumbiganon, Tavitiya Sudjaritruk and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 7 countries.

Weiwei MuClinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Adam W BartlettThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Torsak BunupuradahHIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Kulkanya ChokephaibulkitDepartment of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nagalingeswaran KumarasamyYRGCARE Medical Centre, CART CRS, Chennai, India.
Penh Sun LyNational Centre for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia.
Rawiwan HansudewechakulChiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
Lam Van NguyenNational Hospital of Pediatrics, Hanoi, Vietnam.
Pagakrong LumbiganonDepartment of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Tavitiya SudjaritrukDepartment of Pediatrics, Faculty of Medicine, and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Thahira A Jamal MohamedPediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
Nik Khairulddin Nik YusoffHospital Raja Perempuan Zainab II, Kelantan, Malaysia.
Khanh Huu TruongChildren's Hospital 1, Ho Chi Minh City, Vietnam.
Viet Chau DoChildren's Hospital 2, Ho Chi Minh City, Vietnam.
Moy Siew FongHospital Likas, Kota Kinabalu, Malaysia.
Revathy NallusamyPenang Hospital, Penang, Malaysia.
Nia KurniatiCipto Mangunkusumo-Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
Dewi Kumara WatiSanglah Hospital, Udayana University, Bali, Indonesia.
Annette H SohnTREAT Asia/amfAR-The Foundation for AIDS Research, Bangkok, Thailand.
Azar KariminiaThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Fujie ZhangClinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
TREAT Asia Pediatric HIV Observational Database of IeDEA Asia-Pacific
Beijing Ditan Hospital · CNCapital Medical University · CNChiang Mai University · THChiangRai Prachanukroh Hospital · THChildren's Hospital 1 · VNChildren's Hospital 2 · VNHIV Netherlands Australia Thailand Research Collaboration · THHospital Kuala Lumpur · MYHospital Raja Perempuan Zainab II · MYKhon Kaen University · THMahidol University · THNational Center for HIV/AIDS, Dermatology and STD · KHNational Hospital of Pediatrics · VNPenang Adventist Hospital · MYRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo · IDUdayana University · IDYR Gaitonde Centre for AIDS Research and Education · IN

Funding

The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
NIAID NIH HHS U01 AI069907
6 · The paper itself

Abstract

backgroundVirologic failure is a major threat to maintaining effective combination antiretroviral therapy, especially for children in need of lifelong treatment. With efforts to expand access to HIV viral load testing, our understanding of pediatric virologic failure is evolving.

settingAn Asian cohort in 16 pediatric HIV services across 6 countries.

methodsFrom 2005 to 2014, patients younger than 20 years who achieved virologic suppression and had subsequent viral load testing were included. Early virologic failure was defined as a HIV RNA ≥1000 copies per milliliter within 12 months of virologic suppression, and late virologic as a HIV RNA ≥1000 copies per milliliter after 12 months following virologic suppression. Characteristics at combination antiretroviral therapy initiation and virologic suppression were described, and a competing risk time-to-event analysis was used to determine cumulative incidence of virologic failure and factors at virologic suppression associated with early and late virologic failure.

resultsOf 1105 included in the analysis, 182 (17.9%) experienced virologic failure. The median age at virologic suppression was 6.9 years, and the median time to virologic failure was 24.6 months after virologic suppression. The incidence rate for a first virologic failure event was 3.3 per 100 person-years. Factors at virologic suppression associated with late virologic failure included older age, mostly rural clinic setting, tuberculosis, protease inhibitor-based regimens, and early virologic failure. No risk factors were identified for early virologic failure.

conclusionsAround 1 in 5 experienced virologic failure in our cohort after achieving virologic suppression. Targeted interventions to manage complex treatment scenarios, including adolescents, tuberculosis coinfection, and those with poor virologic control are required.

Indexed as

AdolescentAnti-HIV AgentsAsian PeopleChildFemaleHIV InfectionsHumansMaleRisk FactorsTreatment FailureViral LoadAnti-HIV Agents

Identifiers

PMID30531299
PMCPMC6952284
OpenAlexW2904228139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.